Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms OMNIVORE Study
- 10 Oct 2017 Status changed from not yet recruiting to recruiting.
- 01 Aug 2017 Planned initiation date changed from 30 Jun 2017 to 15 Aug 2017.
- 03 Jul 2017 New trial record